IBDEI054 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1870,1,3,0)
 ;;=3^Drug/chem induced diabetes mellitus with foot ulcer
 ;;^UTILITY(U,$J,358.3,1870,1,4,0)
 ;;=4^E09.621
 ;;^UTILITY(U,$J,358.3,1870,2)
 ;;=^5002576
 ;;^UTILITY(U,$J,358.3,1871,0)
 ;;=E09.628^^3^56^53
 ;;^UTILITY(U,$J,358.3,1871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1871,1,3,0)
 ;;=3^Drug/chem diabetes w oth skin complications
 ;;^UTILITY(U,$J,358.3,1871,1,4,0)
 ;;=4^E09.628
 ;;^UTILITY(U,$J,358.3,1871,2)
 ;;=^5002578
 ;;^UTILITY(U,$J,358.3,1872,0)
 ;;=E09.630^^3^56^54
 ;;^UTILITY(U,$J,358.3,1872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1872,1,3,0)
 ;;=3^Drug/chem diabetes w periodontal disease
 ;;^UTILITY(U,$J,358.3,1872,1,4,0)
 ;;=4^E09.630
 ;;^UTILITY(U,$J,358.3,1872,2)
 ;;=^5002579
 ;;^UTILITY(U,$J,358.3,1873,0)
 ;;=E09.638^^3^56^52
 ;;^UTILITY(U,$J,358.3,1873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1873,1,3,0)
 ;;=3^Drug/chem diabetes w oth oral complications
 ;;^UTILITY(U,$J,358.3,1873,1,4,0)
 ;;=4^E09.638
 ;;^UTILITY(U,$J,358.3,1873,2)
 ;;=^5002580
 ;;^UTILITY(U,$J,358.3,1874,0)
 ;;=E09.65^^3^56^59
 ;;^UTILITY(U,$J,358.3,1874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1874,1,3,0)
 ;;=3^Drug/chem induced diabetes mellitus w hyperglycemia
 ;;^UTILITY(U,$J,358.3,1874,1,4,0)
 ;;=4^E09.65
 ;;^UTILITY(U,$J,358.3,1874,2)
 ;;=^5002583
 ;;^UTILITY(U,$J,358.3,1875,0)
 ;;=E09.69^^3^56^49
 ;;^UTILITY(U,$J,358.3,1875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1875,1,3,0)
 ;;=3^Drug/chem diabetes w oth complication
 ;;^UTILITY(U,$J,358.3,1875,1,4,0)
 ;;=4^E09.69
 ;;^UTILITY(U,$J,358.3,1875,2)
 ;;=^5002584
 ;;^UTILITY(U,$J,358.3,1876,0)
 ;;=E09.649^^3^56^39
 ;;^UTILITY(U,$J,358.3,1876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1876,1,3,0)
 ;;=3^Drug/chem diabetes w hypoglycemia w/o coma
 ;;^UTILITY(U,$J,358.3,1876,1,4,0)
 ;;=4^E09.649
 ;;^UTILITY(U,$J,358.3,1876,2)
 ;;=^5002582
 ;;^UTILITY(U,$J,358.3,1877,0)
 ;;=E08.8^^3^56^30
 ;;^UTILITY(U,$J,358.3,1877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1877,1,3,0)
 ;;=3^Diabetes due to underlying condition w unsp complications
 ;;^UTILITY(U,$J,358.3,1877,1,4,0)
 ;;=4^E08.8
 ;;^UTILITY(U,$J,358.3,1877,2)
 ;;=^5002543
 ;;^UTILITY(U,$J,358.3,1878,0)
 ;;=E09.8^^3^56^55
 ;;^UTILITY(U,$J,358.3,1878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1878,1,3,0)
 ;;=3^Drug/chem diabetes w unsp complications
 ;;^UTILITY(U,$J,358.3,1878,1,4,0)
 ;;=4^E09.8
 ;;^UTILITY(U,$J,358.3,1878,2)
 ;;=^5002585
 ;;^UTILITY(U,$J,358.3,1879,0)
 ;;=E88.01^^3^57^13
 ;;^UTILITY(U,$J,358.3,1879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1879,1,3,0)
 ;;=3^Alpha-1-antitrypsin deficiency
 ;;^UTILITY(U,$J,358.3,1879,1,4,0)
 ;;=4^E88.01
 ;;^UTILITY(U,$J,358.3,1879,2)
 ;;=^331442
 ;;^UTILITY(U,$J,358.3,1880,0)
 ;;=E71.310^^3^57^70
 ;;^UTILITY(U,$J,358.3,1880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1880,1,3,0)
 ;;=3^Long chain/very long chain acyl CoA dehydrogenase deficiency
 ;;^UTILITY(U,$J,358.3,1880,1,4,0)
 ;;=4^E71.310
 ;;^UTILITY(U,$J,358.3,1880,2)
 ;;=^5002870
 ;;^UTILITY(U,$J,358.3,1881,0)
 ;;=E71.311^^3^57^76
 ;;^UTILITY(U,$J,358.3,1881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1881,1,3,0)
 ;;=3^Medium chain acyl CoA dehydrogenase deficiency
 ;;^UTILITY(U,$J,358.3,1881,1,4,0)
 ;;=4^E71.311
 ;;^UTILITY(U,$J,358.3,1881,2)
 ;;=^5002871
 ;;^UTILITY(U,$J,358.3,1882,0)
 ;;=E71.312^^3^57^99
 ;;^UTILITY(U,$J,358.3,1882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1882,1,3,0)
 ;;=3^Short chain acyl CoA dehydrogenase deficiency
 ;;^UTILITY(U,$J,358.3,1882,1,4,0)
 ;;=4^E71.312
 ;;
 ;;$END ROU IBDEI054
